| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1194132B1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 06/16/2004 | EP1165044B1 High potency dihydroergotamine compositions |
| 06/16/2004 | EP1147083B1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| 06/16/2004 | EP1144425B1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 06/16/2004 | EP1119570B1 Tricyclic delta3-piperidines as pharmaceuticals |
| 06/16/2004 | EP1056745B1 6,9-disubstituted 2- trans-(4- aminocyclohexyl) amino]purines |
| 06/16/2004 | EP1014961B1 Treatment of migraine headache using metoclopramide and an nsaid |
| 06/16/2004 | EP0983243B1 Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
| 06/16/2004 | EP0906102B1 A process for regulating vagal tone |
| 06/16/2004 | EP0815080B1 Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
| 06/16/2004 | CN1505640A T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| 06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505631A Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands |
| 06/16/2004 | CN1505630A Pyrazolo[1,5-a]pyridines and medicaments containing thereof |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505623A Benzoaxathiepin derivatives and their use as medicines |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505613A Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| 06/16/2004 | CN1505516A Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances |
| 06/16/2004 | CN1505508A Carbamate compounds for use in preventing or treating movement disorders |
| 06/16/2004 | CN1505507A Carbamate compounds for use in preventing or treating psychotic disorders |
| 06/16/2004 | CN1505506A Carbamate compounds for use in preventing or treating bipolar disorder |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504240A Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof |
| 06/16/2004 | CN1504222A Sobering-up compound preparation |
| 06/16/2004 | CN1504220A Prepared traditional Chinese medicine for soothing the nerves and favouring sleep |
| 06/16/2004 | CN1504201A Medication for nourishing yin and strengthening yang and preparation method |
| 06/16/2004 | CN1504188A Use of 5-hydroxymethyl furfural in preparation of medicine and healthcare product for prevention and treatment of degenerative disease of nervous system and cognize hurt |
| 06/16/2004 | CN1153770C Substitued nitrogen heterocyclic ring as inhibitors of P38 protein kinase |
| 06/16/2004 | CN1153766C Nitroketone compound, its preparing process and pharmaceutical composition containing same |
| 06/16/2004 | CN1153765C 4-aryl-1-phenylalkyl-1,2,3,6-Tetrahydropyridines having neurotrophic and neuroprotective activity |
| 06/16/2004 | CN1153764C Substituted benzylaminopiperidine compounds |
| 06/16/2004 | CN1153759C Novel delta-amino-gamma-hydroxy-omega-aryl-alkane amide compounds |
| 06/16/2004 | CN1153579C Buccal tablets for activating intelligent genes and increasing intelligence quotient |
| 06/16/2004 | CN1153568C Compounds active at a novel position on receptor-operated calcium channel useful for treatment of neurological disorders |
| 06/16/2004 | CA2465554A1 Quinoline derivatives as probes for the diagnosis of diseases in which tau protein accumulates |
| 06/15/2004 | US6750350 Therapy for sexual disorders |
| 06/15/2004 | US6750248 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 06/15/2004 | US6750242 Positive modulators of nicotinic receptor agonists |
| 06/15/2004 | US6750239 Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750237 Pharmaceutical formulations containing zolmitriptan |
| 06/15/2004 | US6750232 2-aminopyridine compounds and use thereof as drugs |
| 06/15/2004 | US6750231 Skin disorders; gastrointestinal disorders |
| 06/15/2004 | US6750228 Uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions |
| 06/15/2004 | US6750227 Method of treatment of neuropsychiatric symptoms in patients with Alzheimer's Disease |
| 06/15/2004 | US6750221 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 06/15/2004 | US6750217 Anticancer agents; cardiovascular disorders; kinase inhibitor |
| 06/15/2004 | US6750202 Inhibitors of procollagen c-proteinase (pcp), for treating fibrosis of the liver |
| 06/15/2004 | US6750026 To diagnose diseases relating to under- or over-expression of hfgan72 receptor ligands; for treatment of obesity, diabetes, anorexia nervosa, bulimia, cachexia, chronic renal failure, congestive heart failure |
| 06/15/2004 | US6750012 For identifying compounds that do not induce motor side effects |
| 06/15/2004 | US6749870 Compositions and methods for the control of smoking |
| 06/15/2004 | US6749851 Applying radiation |
| 06/15/2004 | US6749587 Modular infusion device and method |
| 06/15/2004 | CA2153195C New benzopyran derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 06/15/2004 | CA2126083C Use of app modulators for the manufacture of a medicament for the treatment of amyloidosis |
| 06/15/2004 | CA2088334C Fast dissolving tablet and its production |
| 06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
| 06/10/2004 | WO2004048978A2 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| 06/10/2004 | WO2004048574A1 Immunoreceptor proteins |
| 06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
| 06/10/2004 | WO2004048401A1 Peptides and medicinal compositions containing the same |
| 06/10/2004 | WO2004048391A1 Silicon compounds to be used as ligands for retinoid receptors |
| 06/10/2004 | WO2004048374A1 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 06/10/2004 | WO2004048361A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| 06/10/2004 | WO2004048332A1 Isoindoline derivative |
| 06/10/2004 | WO2004048330A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| 06/10/2004 | WO2004048321A1 Phenylsulfoxide and phenylsulfone derivatives |
| 06/10/2004 | WO2004048317A1 Substituted amides active at the cannabinoid-1 receptor |
| 06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
| 06/10/2004 | WO2004047854A2 Methods for the treatment of alzheimers disease and compositions therefore |
| 06/10/2004 | WO2004047844A1 Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
| 06/10/2004 | WO2004047841A1 Treatment of headache with antipsychotics delivered by inhalation |
| 06/10/2004 | WO2004047837A2 Beta-blockers having antioxidant and nitric oxide-donor activity |
| 06/10/2004 | WO2004047836A1 Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| 06/10/2004 | WO2004047824A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | WO2004047819A2 Composition and its use for treating neuropathic sensory loss |
| 06/10/2004 | WO2004047744A2 3-heterocyclic benzylamide derivatives as potassium channel openers |
| 06/10/2004 | WO2004047727A2 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | WO2004047725A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/10/2004 | WO2004032836A3 Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors |
| 06/10/2004 | WO2004024132A3 Use of no-signal cascade modulators and pharmaceutical composition |
| 06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 06/10/2004 | WO2004016578A3 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004002447A3 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 06/10/2004 | WO2003101950A3 Methods for enhancing motor performance and/or endurance |
| 06/10/2004 | WO2003097656A3 Novel substituted sulfamate anticonvulsant derivatives |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003070191A8 Tamper-resistant transdermal opioid delivery devices |
| 06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
| 06/10/2004 | WO2003048116A3 Esters and amides as ppar-alpha agonists ____________ |